PharmaBoardroom

Last year, Dimitri Livadas made the unconventional leap from Big Pharma to a local Saudi firm, Saudi Chemical Company Holding. In conversation with PharmaBoardroom, he explains the motivating factors behind this decision, including Saudi Arabia's vision for the future, the legacy and growth potential of Saudi Chemical, and the unique opportunity to be part of the country's transformative journey. Saudi Chemical operates across the entire pharmaceutical value chain, from development and manufacturing to commercialization and distribution, and Livadas notes its commitment to driving innovation, advancing healthcare, and fostering collaboration within the industry.   Get the full story at: https://lnkd.in/eFBm-Swt

📖 All you need to know about Swiss pharma regulations 🔝 Switzerland is an indisputable behemoth in the global life sciences industry, home to some of the world’s most iconic pharma companies as well as a host of pioneering biotechs. The local Swiss market is also far from insignificant in size, but navigating it successfully requires expert insight and expertise. 🧠 The Pharma Legal Handbook: Switzerland and The Pharma Legal Handbook: Market Access & HTA: Switzerland provide this insight and expertise abundance. These handbooks, produced in collaboration with leading Swiss law firm  Wenger Plattner are an invaluable resource for all stakeholders already operating in the Swiss pharma market or looking to expand their footprint there. Get your copy of the Pharma Legal Handbook: Switzerland at: https://lnkd.in/dAN-eGwc   And the Pharma Legal Handbook: Market Access & HTA Switzerland at: https://lnkd.in/d-8NzGrF  

Company Spotlight: Legend Biotech ↗ Chinese player Legend Biotech reached a new turning point last month when its Johnson & Johnson-partnered Carvykti became the first BCMA-targeted CAR-T cell therapy to be approved by the FDA for second-line treatment of multiple myeloma. 👀 From its original roots in China to its first FDA approval in 2022, PharmaBoardroom's Amanda Saionz examines how the company has remained uniquely focused on CAR-T cells targeting the BCMA protein and what this new milestone means for its future prospects. Get the full picture at: https://lnkd.in/dAZJwgkp

💉 How far away are we from a HIV vaccine? ⚕ Founded in 1996 to coordinate and promote HIV #vaccine development, IAVI has had a major impact across HIV vaccine development efforts, capacity building in low- and middle-income countries, advocacy work, and access initiatives. 🌥 While there have been several high-profile late-stage failures in HIV vaccine candidate trials, IAVI scientists like Johan Vekemans have not given up hope. 🎯 In conversation with PharmaBoardroom, Vekemans outlines how the germline targeting approach to HIV vaccines could generate broadly neutralising antibodies in humans, thus potentially paving the way to the effective HIV vaccine that has eluded science for over 40 years. Get the full story at https://lnkd.in/eGTZ7BDd

💸 Investment Trends to Watch in Chinese Biotech 👨⚕️ Andrew Ng of leading VC firm VMS Group outlines VMS's significant and growing investments in the healthcare segment and some of the key healthcare investment trends to watch in the Greater China region. 🚧 A Challenging Market for Chinese Biotech Funding: After the hype of the past few years, investors today are more cautious and seeking sustainable growth and realistic valuations 🏢 Hong Kong’s Strategic Position: Hong Kong is a critical hub that bridges East and West, particularly valuable for biotech ventures, and a mediator in the biotech industry amidst evolving geopolitical and economic tensions 🌏 Cross-Border Collaborations: Companies are increasingly leveraging strategic partnerships to access new markets, share expertise, and navigate regulatory landscapes Get the full picture at: https://lnkd.in/gkeAkJRP

FDA India interview, Moderna scraps African vaccine manufacturing plans, CGT approvals 2023, Business development in Asia....This week on PharmaBoardroom 🏭 US FDA India Office Director Sarah McMullen, Ph.D. discusses the importance of maintaining India's role as a global supplier of low-cost generics while navigating the complexities of innovating and producing more complex pharmaceutical products https://lnkd.in/dfvXEyK8 💉 Medicines for Africa (mfa)’s Lenias Hwenda reflects on Moderna’s recent decision not to go ahead with plans for a vaccine manufacturing facility in Kenya, and why local production remains crucial to building Africa’s healthcare autonomy https://lnkd.in/dsfUKiV7 🔬 2023: A Record Year for Cell & Gene Therapy Approvals https://lnkd.in/dzk7x2Kz 💹 Servier's Asia BD Head Cynthia Xin Wang on the evolution of global pharma's business development operations in Asia https://lnkd.in/dPUmViqZ

The regulatory lowdown on Saudi pharma 👀 Saudi Arabia is currently undergoing a once-in-a-lifetime transformation under the ‘Vision 2030’ banner, reshaping the country’s economy, unleashing sweeping societal changes and creating a wealth of new opportunities for savvy international investors. 🏥 Pharma firms are busily adapting to a new reality in Saudi; healthcare reform is already well underway, hospital procurement has been unified in a single body, and new local content requirements have been put in place. 1️⃣ Moreover, the country is positioning itself as a regional epicentre for regulatory affairs and has been pinpointed as an early launch market for new innovations within its region. 🧠 However, local regulatory and legal insight is crucial to navigating the Saudi market’s particularities, which makes The Pharma Legal Handbook: Saudi Arabia an invaluable resource. Prepared in association with STA Law Firm, a leading international law firm, this new guide is a crucial tool for all stakeholders already operating in the Saudi pharma market or looking to expand their footprint there. 📖 The Pharma Legal Handbook: Saudi Arabia gives comprehensive answers to a wide range of regulatory questions on Pricing, Reimbursement, Market Access, Clinical trials, Manufacturing, Patents, Cannabinoids, Orphan Drugs, Localization, Biosimilars & more. Get your copy today at: https://lnkd.in/dAPZy7AR

Swiss Biotech's 2024 Turnaround: Breaking Revenue Records Despite Funding Hurdles While the Swiss biotech sector is inevitably facing many of the same funding challenges as the global industry and is still struggling to make a meaningful comeback from its 2022 slump, the latest report from the Swiss Biotech Association and EY shows the sector’s resilience. Key takeaways from the report include... 💹 Record Revenues: Despite a global funding downturn, the Swiss biotech sector showcased resilience with a revenue spike to CHF 7.3 billion in 2023, a significant leap from the previous year. 💸 Strategic Capital Increases: Investment surged over 50%, with CHF 2 billion raised in 2023, demonstrating a robust appetite for innovative Swiss biotech ventures. 🤝 Dynamic M&A Activity: The industry remained vibrant with key mergers and acquisitions, highlighting ongoing growth and expansion opportunities within the sector. Get the full picture in Amanda Saionz's latest piece at https://lnkd.in/dnJ6DkXh

🎙 As part of PharmaBoardroom's ongoing series on HIV/AIDS, we spoke to International Association of Providers of AIDS Care President & CEO Dr José M. Zuniga. 💡 In a candid and illuminating interview with Patrick Burton, Dr Zuniga outlines why - with PrEP and antiretroviral therapies available - there is no excuse for AIDS-related deaths in 2024; declares that HIV must not be left behind as global stakeholders increase spending on pandemic preparedness; and explains how the current politicisation of HIV is deeply troubling, but nothing new. 🏙 Dr Zuniga also highlights how IAPAC's 'Fast-Track Cities' initiative has helped reduce HIV incidence in major urban centres and why the association is rebranding to reflect a more integrated 'whole health' approach. Get the full picture at: https://lnkd.in/d7ccqx7k

Emerging markets are back...here are the regulatory insights you need to navigate them Post-COVID, emerging markets are once more being seen as promising targets for global pharma, provided the right strategies are in place. Get the regulatory lowdown on China, Brazil, India, Indonesia, Mexico, Turkey & Saudi Arabia with The Pharma Legal Handbook: Top Emerging Markets. Prepared in association with leading local law firms, these guides contain all you need on Regulation, Pricing, Clinical and Preclinical Trials, Marketing, Manufacturing, Trademarks, Patents, and more! Get your copy now at: https://lnkd.in/dKKayA9c